Skip to content

Study · Not a test of the peptide alone · 2007

5 results

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ

Current medical research and opinion1 Mar 2007Cited by 43 (Europe PMC)

PMID17355742 (opens in a new tab)DOI10.1185/030079907x178685 (opens in a new tab)PepBankPUB-17355742
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoEfficacy outcome

    In a diabetes simulation, exenatide increased projected life expectancy versus insulin glargine.

    In plain wordsComputer predictions favored exenatide over insulin glargine for life expectancy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProjected life expectancy
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Mortality · Whole body

    Measurements

    Life expectancy gain
    0.057 years
    versus insulin glargine

    Source sentences

    Summary
    In the base-case analysis exenatide was associated with improvements in life expectancy of 0.057 years and in quality-adjusted life expectancy of 0.442 quality-adjusted life years (QALYs) versus insulin glargine.
    1 context sentence
    Summary · context
    A published and validated computer simulation model of diabetes was used to project long-term complications, life expectancy, quality-adjusted life expectancy and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoEfficacy outcome

    In a diabetes simulation, exenatide increased quality-adjusted life expectancy versus insulin glargine.

    In plain wordsComputer predictions favored exenatide over insulin glargine for quality-adjusted life expectancy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseQuality-adjusted life expectancy
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body

    Measurements

    Quality-adjusted life expectancy gain
    0.442 QALYs
    versus insulin glargine

    Source sentences

    Summary
    In the base-case analysis exenatide was associated with improvements in life expectancy of 0.057 years and in quality-adjusted life expectancy of 0.442 quality-adjusted life years (QALYs) versus insulin glargine.
    1 context sentence
    Summary · context
    A published and validated computer simulation model of diabetes was used to project long-term complications, life expectancy, quality-adjusted life expectancy and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoEfficacy outcome

    The simulation projected fewer cardiovascular complications with exenatide than insulin glargine.

    In plain wordsComputer predictions suggested fewer heart and blood vessel complications with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProjected cardiovascular complications
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Long-term projections demonstrated that exenatide was associated with a lower cumulative incidence of most cardiovascular disease (CVD) complications and CVD-related death than insulin glargine.
    1 context sentence
    Summary · context
    A published and validated computer simulation model of diabetes was used to project long-term complications, life expectancy, quality-adjusted life expectancy and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoEfficacy outcome

    The simulation projected lower cardiovascular mortality with exenatide than insulin glargine.

    In plain wordsComputer predictions suggested fewer cardiovascular deaths with exenatide than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProjected cardiovascular mortality
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Mortality · Cardiovascular

    Source sentences

    Summary
    Long-term projections demonstrated that exenatide was associated with a lower cumulative incidence of most cardiovascular disease (CVD) complications and CVD-related death than insulin glargine.
    1 context sentence
    Summary · context
    A published and validated computer simulation model of diabetes was used to project long-term complications, life expectancy, quality-adjusted life expectancy and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    The diabetes simulation projected exenatide as dominant to cost-effective versus insulin glargine across the evaluated price range.

    In plain wordsComputer predictions suggested exenatide could be cost-effective versus insulin glargine, depending on its price.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableCost effectiveness
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Using the range of cost values, evaluation results showed that exenatide is likely to fall in a range between dominant (cost and life saving) at 20% of the US price and cost-effective (with an ICER of 22,420 pounds per QALY gained) at 100% of the US price, versus insulin glargine.
    1 context sentence
    Summary · context
    A published and validated computer simulation model of diabetes was used to project long-term complications, life expectancy, quality-adjusted life expectancy and direct medical costs.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.